Tuberculosis remains one of the most consequential and underappreciated infectious threats in global health — and new granular data covering 33 years and 204 countries now reveal both the scale of hard-won progress and the structural vulnerabilities that could unravel it, particularly as international health funding contracts at a critical juncture.
The Global Burden of Disease Study 2023 provides the most comprehensive TB burden estimate to date, quantifying mortality, morbidity, and disability-adjusted life-years (DALYs) across all major geographies from 1990 through 2023, stratified by HIV co-infection status and drug-resistance profile. The analysis employs ensemble cause-of-death modeling alongside DisMod-MR 2.1 for simultaneous estimation of incidence, prevalence, and mortality by age and sex — a methodological approach that improves internal consistency compared with earlier estimates. A comparative risk assessment framework additionally quantifies attributable fractions for alcohol use, smoking, and elevated fasting plasma glucose, anchoring TB burden within modifiable lifestyle determinants. Global TB deaths declined roughly 37% over the study period, yet the WHO End TB Strategy targets — a 95% mortality reduction and 90% incidence reduction by 2035 from 2015 baselines — remain sharply off-track, with multidrug-resistant TB (MDR-TB) representing a disproportionate and growing share of remaining burden.
This analysis arrives at a structurally important moment. The post-COVID disruption to TB services caused measurable setbacks in case detection and treatment completion globally, and recent reductions in major donor funding risk compounding those losses. Critically, MDR-TB not only carries higher mortality but demands far longer and more expensive treatment regimens, straining health systems in high-burden countries least equipped to absorb cost shocks. The HIV-TB co-infection stratum deserves particular attention: individuals with HIV face dramatically elevated TB mortality risk, and antiretroviral therapy coverage remains uneven across sub-Saharan Africa and South-Central Asia. The breadth of this GBD analysis — covering modifiable risk factors alongside epidemiological burden — is a strength, though observational modeling studies of this scale carry inherent uncertainty in data-sparse regions. Nonetheless, the policy signal is clear: TB control is measurably off-trajectory, and funding contractions now would likely translate to preventable mortality surges within the decade.